Abstract:The rapid development of a stereoselective route for CXCR7 antagonist ACT-1004-1239 was needed, as the large-scale chromatographic separation of enantiomers was not a viable option for a resupply campaign that targeted >30 kg of API. The key to success was the stereoselective reduction of a chiral enamine derived from inexpensive (S)-α-methylbenzylamine. The reduction showed good selectivity for the desired cis-3R,4S-isomer, and the pure diastereomer (d.r. >98:2) was isolated as its TFA salt. After removal of the ethylbenzyl group and amide coupling with 5-(2,4-difluorophenyl)isoxazole-3-carboxylic acid, the enantiopure cis-3R,4S-amide was isolated. The subsequent epimerization of the 3-position adjacent to the methyl ester turned out to be a formidable challenge, as the standard conditions with NaOMe led to the formation of a thermodynamic mixture of the cis and trans isomers (final ratio of ∼1:4). Therefore, a new procedure was developed in which the methyl ester was transesterified in situ to the isopropyl ester with KOiPr in iPrOH, followed by epimerization to the trans-iPr-ester (final cis:trans ratio 5:95). After saponification with aqueous KOH, the desired trans-3S,4S-acid was isolated in overall 76% yield. After amide coupling and Boc deprotection, the final reductive amination with cyclopropanecarboxaldehyde was also vastly improved. A novel NaBH(OAc)3 solution in DMSO was used for the reaction and cleanly provided the API with high purity after simple aqueous quench without the need for any solvent switches or aqueous workups. As a proof of concept, 240 g of API was produced in house with the novel stereoselective route, which was then also used to produce over 30 kg of GMP material at an external manufacturer for Phase 2 clinical studies.

Development of Scalable Processes for the Preparation of 4-(chloromethyl)-1-cyclohexyl-2-(trifluoromethyl)benzene: A Key Intermediate for Siponimod

Asymmetric Synthesis of N-protected 3-Methylpiperidin-2-one and Its Diastereoisomer

Improved Synthesis of Methyl 3-Oxo-2,6,6-trimethylcyclohex-1-ene-1-carboxylate, an A-ring Intermediate for (±)Strigol

Synthesis of 6-bromo-4,4-dimethylthiochroman

A new procedure for the synthesis of 2-[(4-dodecyloxyphenyl)sulfonyl]butanoic acid

Synthesis of N-Methyl-4-aminobenzyl Sulfonamide

A Novel Asymmetric Synthesis of Cis-(3r, 4R)-N-(tert-butoxycarbonyl)-4-methyl-3-(methylamino) Piperidine

Synthesis and Chiral Resolution of 2,2- Dimethylcyclopropane Carboxylic Acid

Convenient Synthesis and Characterization of Novel 4-[2-ethoxy-5-(4-methyl-1-piperazinesulphonyl)benzamido]-3-isobutyl-1-methyl-1h-pyrazole-5-carboxamide: Key Precursor for Isobutyl Sildenafil

Scalable Process of Spiro(cyclopropane)oxazepane Pyridine Carboxylic Acid Through Kulinkovich, Mitsunobu, and Pd-Catalyzed Intramolecular C–N Coupling

Development of a Large-Scale Asymmetric Process for Tert-Butanesulfinamide

Development of A Large Scale Asymmetric Synthesis of the Glucocorticoid Agonist Bi 653048 Bs H3po4

Scalable Synthesis of Antihistamines and Sensipar via Intensified Hydrogen Borrowing Methodology

Industry-Oriented Route Evaluation and Process Optimization for the Preparation of Brexpiprazole

Development of a Scalable, Chromatography-Free Synthesis of t-Bu-SMS-Phos and Application to the Synthesis of an Important Chiral CF 3 -Alcohol Derivative with High Enantioselectivity Using Rh-Catalyzed Asymmetric Hydrogenation.

Development of a Scalable, Stereoselective Second-Generation Route for CXCR7 Antagonist ACT-1004-1239 via Chiral Enamine Reduction and a Novel Telescoped Sequence of Transesterification, cis -to- trans Epimerization, and Saponification

Development of a Safe, Efficient, and Scalable Process for the Synthesis of Midazolam Hydrochloride

Building a Quaternary Stereogenic Center on Dihydroazaindole Carboxylic Acid through Scalable Process Development

Development Of A Concise, Scalable Synthesis Of A Ccr1 Antagonist Utilizing A Continuous Flow Curtius Rearrangement

Scalable and Integrated Four-step Continuous-Flow Synthesis of Ibuprofen Using a Zinc-Catalyzed 1,2-Aryl Migration Strategy

Development of a Kilogram-Scale Chemical Process for a Chiral Spirocyclic Isoxazolone